Odyssey Group International Inc. ODYY Archives

ThursdayDec 01, 2022 9:00 am

Odyssey Health, Inc. (ODYY) To Give Corporate Update at Scheduled Annual Meeting of Stockholders in January 2023

Odyssey is set to hold its Annual Meeting of Stockholders on January 12, 2023 The meeting promises an excellent podium to update shareholders on the company’s progress throughout the 2022 calendar year as well as its plans for the future Odyssey has so far achieved vital milestones such as progress in its ONP-002 novel compound on the treatment of concussions, patent protection filing for its Nasal Device, and the expansion of its executive team It looks to take advantage of the meeting to draw stockholders' views and opinions on specific topics while also offering them a platform to contribute to…

TuesdayNov 29, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Development of Neuropharmaceuticals for TBIs and CNS Maladies, Portends Competitiveness in Area of Unmet Medical Needs

A growing chorus of concerns about brain concussions resulting from athletic events is helping to propel new interest in developing pharmaceuticals to treat this “unmet medical need” Concussion treatments have largely focused on simple rest, but medical product developer Odyssey Health Inc. is developing a potential treatment to reduce brain inflammation so needed therapy can get to the site of a brain injury Odyssey is also developing solutions for other central nervous system troubles, such as the highly fatal childhood disease Niemann-Pick type C, and nerve gas exposure sickness The neuropharmaceutical market is forecast to have a great deal of…

WednesdayNov 23, 2022 10:59 am

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has released an update on its concussion drug-development program. According to the release, in March 2022 the company acquired key intellectual property (“IP”) to a concussion drug, along with all rights to that drug. During the past few months, the company has completed strategic steps to develop the drug, including appointing two new members of the management team with expertise in progressing drugs through the clinical phase and to the market; completing an FDA-required IND in order to move forward…

MondayNov 21, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies

Brain injuries affect all aspects of society, from recreational youth athletics to military trauma interventions Despite the commonality of brain concussion injuries — more than 5 million a year in the United States alone — no FDA-approved therapy exists Medical technology innovator Odyssey Health Inc. is working toward a commercialized product treatment solution to the unmet need of concussion injuries Odyssey’s product for treating brain concussion has recently completed a series of human and animal safety trials and is now being prepped for Phase II/III trials focused on proving efficacy The product administers neurosteroids across the blood-brain barrier to stop…

TuesdayNov 15, 2022 2:04 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Announces Upcoming Annual Meeting of Stockholders

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has scheduled its Annual Meeting of Stockholders; the meeting is slated for Jan. 12, 2023. According to the announcement, any proposals to be considered for the meeting should be sent to the company’s principal executive offices in Las Vegas; all proposals must comply with the procedures for stockholder proposals in the company's bylaws and need to be received by the close of business on Nov. 25, 2022. The company will file the official Notice of Annual Meeting and Proxy Statement…

MondayNov 14, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device

Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder The application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the effective use of the device and a proven safety profile for the company’s concussion pharmaceutical treatment Michael Redmond, the company’s CEO, has expressed the company’s pleasure in the functionality of the device, citing how it provides a significant opportunity and advantage for the treatment of…

WednesdayNov 09, 2022 9:45 am

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Poised to Potentially Reduce Long-Term Risks Associated with Concussion

Odyssey Health is a medical company specializing in the development of unique, life-saving medical products that provide solutions to unmet clinical needs, one of which is concussion, which currently does not have an FDA-approved drug The company has developed the PRV-002 drug candidate, which is designed to be administered intranasally where pre-clinical results have shown to be effective in treating a concussion within 30 minutes of administration Through its drug candidate, Odyssey hopes to reduce the risks and potential for long-term consequences associated with concussions Up until Olympic gold medalist Katie Weatherston was forced into retirement following a series of…

MondayNov 07, 2022 9:45 am

New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments

Odyssey Health Inc. is a medical product developer with a mission of filling unmet needs when it comes to acute emergencies involving patients’ central nervous systems The company recently announced the formation of a wholly owned subsidiary to help Odyssey develop its products as they move through the regulatory process Odyssey’s solutions include a breath-powered intranasal delivery mechanism and synthetic neurosteroids designed to provide rapid-response treatment for patients with concussions and a highly fatal pediatric neurological disease Odyssey Health also is developing solutions for heart disease detection, obstructed-airway choking and nerve agent exposure The concussion therapeutic solution recently completed Phase…

ThursdayNov 03, 2022 12:57 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Announces Expansion of Executive Team

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, is expanding its executive team. The expansion is part of ODYY’s support of and commitment to Odyssey NeuroPharma, the company’s newest entity. Additions to the executive team include Erik Emerson, named chief commercial officer, and Greg Gironda, named chief operating officer. These two together have more than five decades of experience in commercializing innovative pharmaceutical compounds with leading pharmaceutical companies; the pair will work to advance Odyssey’s concussion treatment and Niemann-Pick treatment. According to the announcement, more than 5 million…

TuesdayNov 01, 2022 10:41 am

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Files for Patent Protection on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Odyssey Health (OTC: ODYY) has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As previously announced, Odyssey’s recently completed phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination. “We were very pleased with the functionality and performance of the Nasal Device during the phase I study and its administration of Odyssey’s PRV-002 concussion drug,” said Michael Redmond, CEO of Odyssey. “The ability to get drugs for neurological conditions delivered directly into the brain rapidly at effective levels while simultaneously having less concern for side effects…

Site Search

Company Search

Tag: Odyssey Group International Inc. ODYY